natgillin/translations-raw huggingface dataset:
The European Commission granted a marketing authorisation valid throughout the European Union for Ryzodeg on 21 January 2013. 
Evropska komisija je dovoljenje za promet z zdravilom Ryzodeg, veljavno po vsej Evropski uniji, izdala 21. januarja 2013.
What measures are being taken to ensure the safe and effective use of Ryzodeg? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ryzodeg?
The full EPAR for Ryzodeg can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ryzodeg je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Because the dose requirements in young children may not be stable and because they cannot express symptoms of hypoglycaemia, Ryzodeg is not suitable for children aged under 2 years. 
Ker bi lahko bil zahtevani odmerek pri majhnih otrocih nestabilen in ker ne morejo izraziti simptomov hipoglikemije, zdravilo Ryzodeg ni primerno za otroke, mlajše od dveh let.
Other information about Ryzodeg 
Druge informacije o zdravilu Ryzodeg
What benefit has Ryzodeg shown during the studies? 
Kakšne koristi je zdravilo Ryzodeg izkazalo med študijami?
This is a summary of the European public assessment report (EPAR) for Ryzodeg. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ryzodeg.
The dose of Ryzodeg is determined individually for each patient. 
Ustrezen odmerek se določi za vsakega bolnika posebej.
For more information about treatment with Ryzodeg, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Ryzodeg preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ryzodeg have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ryrzodeg upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Ryzodeg insulin degludec / insulin aspart 
Ryzodeg insulin degludek/insulin aspart
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ryzodeg. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Ryzodeg is injected once or twice a day, at mealtimes. 
Zdravilo Ryzodeg se injicira enkrat ali dvakrat na dan ob obrokih.
The CHMP decided that Ryzodeg's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Ryzodeg večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
It is available as a solution for injection in a cartridge (100 units/ml) and in a pre-filled pen (100 units/ml). 
Na voljo je kot raztopina za injiciranje v injekcijskem vložku (100 enot/ml) in v napolnjenem injekcijskem peresniku (100 enot/ml).
What is the risk associated with Ryzodeg? 
Kakšna tveganja so povezana z zdravilom Ryzodeg?
The Committee concluded that Ryzodeg is generally safe and its side effects are comparable to those of other insulin analogues. 
Odbor je ugotovil, da je zdravilo Ryzodeg na splošno varno in da so njegovi neželeni učinki primerljivi z neželenimi učinki drugih insulinskih analogov.
Meanwhile, insulin aspart is absorbed faster by the body than human insulin, and therefore it starts to work as soon as it is injected and has a short duration of action. 
Po drugi strani se insulin aspart v telesu hitreje absorbira kot človeški insulin, zato začne delovati takoj ob injiciranju, njegovo delovanje pa je kratkotrajno.
The place for injection should be altered with each injection to reduce the risk of developing fatty lumps under the skin that can affect the amount of Ryzodeg absorbed into the blood. 
Mesto injiciranja je treba menjati ob vsakem injiciranju, da se zmanjša tveganje za razvoj maščobnih bulic pod kožo, ki lahko vpliva na količino absorbiranega zdravila Ryzodeg.
In the study in children, the combined used of Ryzodeg and insulin aspart was at least as effective as insulin detemir and insulin aspart, with average HbA1c reductions of 0.27 and 0.23 percentage points respectively. 
V študiji pri otrocih je bila kombinirana uporaba zdravila Ryzodeg in insulina asparta vsaj tako učinkovita kot insuin detemir in insulin aspart, pri tem pa so se ravni HbA1c povprečno znižale za 0,27 oziroma 0,23 odstotne točke.
The most frequently reported side effect during treatment with Ryzodeg is hypoglycaemia (low blood glucose levels). 
Najpogosteje opisan neželeni učinek med zdravljenjem z zdravilom Ryzodeg je hipoglikemija (nizke ravni glukoze v krvi).
Ryzodeg has been studied in one main study involving 548 adults with type 1 diabetes and in four main studies involving 1,866 adults with type 2 diabetes. 
Zdravilo Ryzodeg je bilo raziskano v eni glavni študiji, ki je vključevala 548 odraslih s sladkorno boleznijo 1, in v štirih glavnih študijah, ki so vključevale 1 866 odraslih s sladkorno boleznijo tipa 2.
All of the studies measured the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood attached to glucose. 
V vseh študijah so merili raven glikoziliranega hemoglobina (HbA1c) oziroma delež hemoglobina v krvi, vezanega na glukozo.
The replacement insulin acts in the same way as natural insulin, and helps glucose from the blood to enter cells. 
Nadomestni insulin deluje na enak način kot naravno tvorjeni insulin in pomaga pri prehodu glukoze iz krvi v celice.
Why has Ryzodeg been approved? 
Zakaj je bilo zdravilo Ryzodeg odobreno?
In the studies in type 2 diabetes, Ryzodeg was either given alone or in combination with other antidiabetes medicines. 
V študijah pri sladkorni bolezni tipa 2 so zdravilo Ryzodeg dajali samostojno ali v kombinaciji z drugimi antidiabetiki.
The differences mean that insulin degludec is absorbed more slowly by the body. 
Razlika je v tem, da telo insulin degludek počasneje absorbira.
Insulin degludec and insulin aspart are slightly different from human insulin. 
Insulin degludek in insulin aspart se nekoliko razlikujeta od človeškega insulina.
The active substances in Ryzodeg, insulin degludec and insulin aspart, are produced by a method known as ‘recombinant DNA technology': they are made by a yeast that has received a gene (DNA), which makes the yeast able to produce them. 
Zdravilni učinkovini v njem, insulin degludek in insulin aspart, se proizvedeta z metodo, znano kot „tehnologija rekombinantne DNK“: proizvede ju kvasovka, ki prejeme gen (DNK), s katerim lahko tvori te beljakovine.
Injecting Ryzodeg at a main meal provides long-acting insulin to control blood sugar until the next dose as well as short-acting insulin to help deal with the extra sugar from the meal. 
Injiciranje zdravila Ryzodeg ob glavnem obroku zagotavlja dolgotrajno delovanje insulina za uravnavanje sladkorja v krvi do naslednjega odmerka in hitrodelujoči insulin, ki pomaga obvladovati dodatni sladkor iz obroka.
Ryzodeg is used to treat diabetes in adults, adolescents and children from 2 years of age. 
Zdravilo Ryzodeg se uporablja za zdravljenje odraslih, mladostnikov in otrok, starejših od dveh let, ki imajo sladkorno bolezen.
Ryzodeg is a replacement insulin for the insulin normally made by the body. 
Zdravilo Ryzodeg je nadomestni insulin za insulin, ki ga v normalnih pogojih proizvaja telo.
The reduction in HbA1c levels (in percentage points) was 0.7 in patients with type 1 diabetes and between 1 and 1.7 across the trials in patients with type 2 diabetes. 
Ravni HbA1c so se pri bolnikih s sladkorno boleznijo tipa 1 znižale za 0,7 odstotne točke, pri bolnikih s sladkorno boleznijo tipa 2 pa so se v različnih preskušanjih znižale za od 1 do 1,7 odstotne točke.
It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh. 
Zdravilo se injicira pod kožo v trebušno steno (sprednji del pasu), nadlaket ali stegno.
It also noted that in the studies with adults Ryzodeg reduces the risk of hypoglycaemia during the night in patients with type 1 and type 2diabetes. 
Prav tako je upošteval, da je v študijah pri odraslih zdravilo Ryzodeg zmanjšalo tveganje za pojav hipoglikemije ponoči pri bolnikih s sladkorno boleznijo tipa 1 in 2.
Ryzodeg was given once a day at mealtime with insulin aspart given at other mealtimes and this treatment was compared with treatment comprising insulin detemir given once or twice a day with insulin aspart given at all mealtimes. 
Zdravilo so dajali enkrat na dan ob obroku, pri drugih obrokih pa insulin aspart, in to zdravljenje primerjali z zdravljenjem z insulinom detemirom, ki so ga dajali enkrat ali dvakrat na dan, pri vseh obrokih pa tudi insulin aspart.
Ryzodeg has also been studied in one main study in 362 children aged between 1 and 17 years with type 1 diabetes. 
Zdravilo Ryzodeg so proučevali tudi v eni glavni študiji pri 362 otrocih s sladkorno boleznijo tipa 1, starih od 1 do 17 let .
In the studies in type 1 diabetes, patients also received injections of rapid acting insulin at other mealtimes. 
V študijah pri sladkorni bolezni tipa 1 so bolniki prejemali tudi injekcije hitrodelujočega insulina ob preostalih obrokih.
Ryzodeg is a medicine that contains the active substances insulin degludec and insulin aspart. 
Ryzodeg je zdravilo, ki vsebuje zdravilni učinkovini insulin degludek in insulin aspart.
The studies compared Ryzodeg given at mealtimes with insulin glargine or insulin detemir (long-acting insulins), or with biphasic insulin (an insulin formulation consisting of a mixture of intermediate- and rapid-acting insulin). 
V študijah so zdravilo Ryzodeg, ki se ga daje ob obrokih, primerjali z insulinom glarginom ali insulinom detemirom (insulinoma z dolgotrajnim delovanjem) ali z dvofaznim insulinom (insulinom, sestavljenim iz kombinacije insulina s srednje dolgim in hitrim delovanjem).
How does Ryzodeg work? 
Kako zdravilo Ryzodeg deluje?
What is Ryzodeg used for? 
Za kaj se zdravilo Ryzodeg uporablja?
In type 1 diabetes, Ryzodeg is used with rapid-acting insulin, which is injected at other mealtimes. 
Pri sladkorni bolezni tipa 1 se zdravilo Ryzodeg uporablja v kombinaciji s hitrodelujočim insulinom, ki se ga injicira ob preostalih obrokih.
How has Ryzodeg been studied? 
Kako je bilo zdravilo Ryzodeg raziskano?
How is Ryzodeg used? 
Kako se zdravilo Ryzodeg uporablja?
What is Ryzodeg? 
Kaj je zdravilo Ryzodeg?
The studies in adults showed that Ryzodeg was at least as effective as long-acting insulins and biphasic insulin in controlling blood glucose levels in patients with type 1 and type 2 diabetes. 
Študije so pokazale, da je bilo zdravilo Ryzodeg pri uravnavanju ravni glukoze v krvi pri bolnikih s sladkorno boleznijo tipa 1 in 2 vsaj tako učinkovito kot dolgodelujoči insulini in dvofazni insulin.
The CHMP concluded that Ryzodeg is effective in controlling blood glucose levels in adults, adolescents and children aged over 2 years with diabetes. 
CHMP je zaključil, da je zdravilo Ryzodeg učinkovito pri uravnavanju ravni glukoze v krvi pri bolnikih s sladkorno boleznijo tipa 1 in 2.
MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration 
Jakost Farmacevtska oblika
However, these conditions are reported more frequently in the younger children in general. 
Vendar pa o teh stanjih na splošno pogosteje poročajo pri mlajših otrocih.
Date of first authorisation: 31 July 2014 Date of latest renewal: 19 July 2018 
Datum prve odobritve: 31. julij 2014 Datum zadnjega podaljšanja: 19. julij 2018
Long term safety data is not available. 
Dolgoročni podatki o varnosti niso na voljo.
There have been cases reported where this increase to abnormal high values was already observed after 4 weeks. 
Poročali so o primerih, kjer so to povečanje na nenormalno velike vrednosti opazili že po 4 tednih.
This effect is considered clinically not relevant. 
Ta učinek ne velja za klinično pomembnega.
Patients should take the entire dose. 
Bolniki morajo vzeti celoten odmerek.
Ataluren does not distribute into red blood cells. 
Ataluren se ne porazdeli v rdeče krvne celice.
Final study report to be submitted Due date: 
Končno poročilo o študiji bo oddano do roka:
Characteristic in specific groups of subjects or patients 
Značilnosti pri posebnih skupinah oseb ali bolnikov
Frequency not known 
Pogostnost ni znana
Ataluren should be administered orally every day in 3 doses. 
Ataluren je treba dajati peroralno vsak dan v 3 odmerkih.
Dehydration may be a contributing factor in some of these cases. 
K pojavu nekaterih od teh primerov bi lahko prispevala dehidracija.
Frequency groupings are defined to the following convention: very common (≥ 1/10) and common (≥ 1/100 to < 1/10). 
Razvrstitev pogostnosti je v skladu z naslednjim dogovorom: zelo pogosti (≥ 1/10) in pogosti (≥ 1/100 do < 1/10).
However, the magnitude of this effect could be larger for the 40 mg dose of telmisartan. 
Vendar pa je lahko obseg tega učinka večji pri odmerku 40 mg telmisartana.
Your doctor or pharmacist will tell you the exact number of sachets and what strength to take at each time. 
Zdravnik ali farmacevt vam bo natančno povedal, koliko vrečic in katero jakost morate vzeti ob določenem času.
Delayed or missed dose 
Zamujen ali izpuščen odmerek
Do not stop taking Translarna without talking to your doctor. 
Ne prenehajte jemati zdravila Translarna, ne da bi se posvetovali z zdravnikom.
Separation between ataluren and placebo was maintained from Week 16 through the end of the study. 
Razlika med atalurenom in placebom se je ohranila od 16. tedna do konca študije.
- If you are allergic to ataluren or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na ataluren ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
As a precautionary measure, it is recommended to avoid the use of ataluren during pregnancy. 
Kot previdnostni ukrep se priporoča izogibanje uporabi atalurena med nosečnostjo.
Tell your doctor if you are taking, have recently taken, or might take any other medicines. 
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
A risk to the breastfed new-borns/infants cannot be excluded. 
Tveganja za dojene novorojenčke/dojenčke ni mogoče izključiti.
No effects on male and female fertility were observed, but effects of early juvenile treatment on fertility during adulthood were not investigated. 
Učinkov na plodnost pri moških in ženskah niso opazili, vendar pa niso bili raziskani učinki zdravljenja v zgodnji mladosti na plodnost v odraslem obdobju.
Hypertension with use of concomitant systemic corticosteroids 
Hipertenzija, povezana s sočasno uporabo sistemskih kortikosteroidov
The pharmacokinetics of ataluren has been evaluated in study PTC124-GD-030 over a duration of 4 weeks. 
Farmakokinetiko atalurena so ovrednotili v študiji PTC124-GD-030, ki je trajala 4 tedne.
Higher ataluren exposure was associated with potential decrease in efficacy. 
Večja izpostavljenost atalurenu je bila povezana s potencialnim zmanjšanjem učinkovitosti.
Description of selected adverse reactions (laboratory abnormalities) 
Opis izbranih neželenih učinkov (laboratorijske nenormalnosti)
What you need to know before you take Translarna 3. 
Kaj morate vedeti, preden boste vzeli zdravilo Translarna 3.
In a 48-week open-label extension study in patients with nmDMD patients who were ambulant or nonambulant demonstrated a similar safety profile. 
V 48-tedenski odprti podaljšanji študiji pri bolnikih z nmDMD so bolniki, ki so bili pokretni ali nepokretni, kazali podoben varnostni profil.
Due to the low number of other races included in the clinical studies, no conclusions can be drawn on the effect of UGT1A9 in other ethnic groups. 
Zaradi majhnega števila drugih ras, vključenih v klinične študije, ni mogoče podati nobenih zaključkov o vplivu UGT1A9 pri drugih etničnih skupinah.
Almac Pharma Services (Ireland) Limited Finnabair Industrial Estate Dundalk, Co. Louth, A91 P9KD Ireland 
Almac Pharma Services (Ireland) Limited Finnabair Industrial Estate Dundalk, Co. Louth, A91 P9KD
The onset of reduction in relative bioavailability is estimated to occur approximately 60 hours after the first dose. 
Relativna biološka uporabnost se po ocenah začne zmanjševati približno 60 ur po prvem odmerku.
Remember to take the next dose on time. 
Ne pozabite vzeti naslednjega odmerka ob pravem času.
Do not give this medicine to children under the age of 2 years or weighing less than 12 kg as it has not been tested in this group of patients. 
Zdravilo se ne sme dajati otrokom, mlajšim od 2 let ali s telesno maso manj kot 12 kg, saj pri tej skupini bolnikov ni bilo preskušeno.
Patients who do not have a nonsense mutation 
Bolniki brez nesmiselne mutacije
The safety and efficacy of Translarna in children <12kg and aged 6 months to 2 years have not yet been established. 
Varnost in učinkovitost zdravila Translarna pri otrocih < 12 kg in starih od 6 mesecev do 2 let, še nista bili dokazani.
It is important to take the correct dose. 
Pomembno je, da se daje pravilen odmerek.
This means that there is more evidence to come about this medicine. 
To pomeni, da se pričakujejo dodatni dokazi o zdravilu.
Weight Range (kg) 
Razpon telesne mase (kg)
The majority of patients in all treatment groups were Caucasian (90%). 
Večina bolnikov v vseh skupinah, ki so prejemale zdravljenje, je bila belcev (90 %).
Tell your doctor if you are taking any of the following medicines: 
Obvestite zdravnika, če jemljete katero koli od naslednjih zdravil: Zdravilo
Open the sachet only at the time you are taking the medicine and use the entire amount from the sachet. 
Odprite vrečico šele takrat, ko boste vzeli zdravilo, in uporabite celotno vsebino vrečice.
The majority of patients in both treatment groups were Caucasian (76%). 
Večina bolnikov v obeh skupinah, ki sta prejemali zdravljenje, je bila belcev (76 %).
Increasing the dose above the recommended dose may be associated with reduced effectiveness. 
Dajanje odmerkov, večjih od priporočenih, je lahko povezano z manjšo učinkovitostjo.
Translarna is available in packs containing 30 sachets. 
Zdravilo Translarna je na voljo v pakiranjih, ki vsebujejo 30 vrečic.
Do not use this medicine after the expiry date, which is stated on the carton and sachet after ‘EXP'. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in vrečici poleg oznake "EXP".
In a 26-week transgenic mouse model for carcinogenicity, no evidence of carcinogenicity was found. 
Pri transgenem mišjem modelu za proučevanje rakotvornosti po 26 tednih niso odkrili nobenih znakov rakotvornosti.
Females were not studied in nmDMD clinical trials. 
Žensk v kliničnih preskušanjih pri bolnikih z nmDMD niso proučevali.
Time to 10% worsening in 6MWD was defined as the last time that 6MWD was not 10% worse than baseline. 
Čas do 10-% poslabšanja v 6MWD je opredeljen kot zadnja časovna tička, ko 6MWD ni bila za 10 % slabša kot ob izhodišču.
Other medicines and Translarna 
Druga zdravila in zdravilo Translarna
Pharmacotherapeutic group:Other drugs for disorders of the musculo-skeletal system, ATC code: M09AX03 
Farmakoterapevtska skupina: druga zdravila za zdravljenje bolezni mišično-skeletnega sistema, oznaka ATC: M09AX03
Co. Armagh BT63 5UA 
Co. Armagh BT63 5UA Velika Britanija
In addition to the above mentioned effects, several other less adverse effects were found in the repeat dose studies; in particular decreased body weight gain, food intake and increased liver weight without a histological correlate and of unclear clinical significance. 
Poleg zgoraj navedenih učinkov so v študijah s ponovljenimi odmerki opazili še več drugih manj škodljivih neželenih učinkov, zlasti zmanjšano pridobivanje telesne mase, zmanjšan vnos hrane ter povečano maso jeter brez histološke povezave in z nejasnim kliničnim pomenom.
Morning 
Zjutraj
In vitro, ataluren is 99.6% bound to human plasma proteins and the binding is independent of plasma concentration. 
In vitro se 99,6 % atalurena veže na človeške plazemske beljakovine, pri čemer vezava ni odvisna od plazemske koncentracije.
Translarna is used to treat patients aged 2 years and older, who are able to walk. 
Zdravilo Translarna se uporablja za zdravljenje bolnikov, starih 2 let ali več, ki lahko hodijo.
Presence of radioactivity in pup plasma confirmed absorption from the milk by the pups. 
Prisotnost radioaktivnosti v plazmi mladičev je potrdila absorpcijo iz mleka.
These results indicate that ataluren 40 mg/kg/day slows the loss of walking ability in nmDMD patients. 
Ti rezultati kažejo, da ataluren 40 mg/kg/dan upočasni izgubo zmožnosti hoje pri bolnikih z nmDMD.
In the event of a suspected overdose, supportive medical care should be provided including consulting with a healthcare professional and close observation of the clinical status of the patient. 
Ob sumu, da je prišlo do prevelikega odmerjanja, je treba zagotoviti podporno oskrbo, ki vključuje posvet z zdravstvenim delavcem in skrbno opazovanje kliničnega stanja bolnika.
Take Translarna by mouth 3 times per day; in the morning, midday and evening. 
Zdravilo Translarna jemljite skozi usta 3-krat na dan, in sicer zjutraj, zgodaj popoldne in zvečer.
If you have any kidney problem, your doctor should check your kidney function regularly. 
Če imate kakršne koli težave z ledvicami, mora zdravnik redno preverjati delovanje vaših ledvic.
It is hypothetised that the in vivo dose response relationship may also be bell-shaped, but in vivo data were too limited to confirm this hypothesis in a mouse model for nmDMD and in humans. 
Domneva se, da bi lahko bila in vivo povezava med odmerkom in odzivom prav tako v obliki zvona, vendar pa so bili podatki in vivo preveč omejeni, da bi lahko potrdili to hipotezo pri mišjem modelu za nmDMD in pri človeku.
Safety data from 28 weeks of therapy showed a similar safety profile of ataluren in patients 2-5 years as compared with patients aged 5 years and older. 
Podatki o varnosti iz 28-tedenskega zdravljenja so pokazali podoben profil varnosti atalurena za bolnike, stare od 2 do 5 let, v primerjavi z bolniki, starimi 5 in več let.
Patients who experience dizziness should use caution when driving, cycling or using machines. 
Bolniki, pri katerih se pojavlja omotica, morajo biti pri vožnji, kolesarjenju ali upravljanju strojev previdni.
In both studies, 1/232 (0.43%) patients treated with ataluren discontinued due to an adverse reaction of constipation and 1/172 (0.58%) placebo patients discontinued treatment due to an adverse reaction of disease progression (loss of ambulation). 
V obeh študijah je 1/232 (0,43 %) bolnikov, zdravljenih z atalurenom, prekinilo zdravljenje zaradi neželenega učinka konstipacije in 1/172 (0,58 %) bolnikov, ki so prejemali placebo, je prekinilo zdravljenje zaradi neželenega učinka napredovanja bolezni (izguba mobilnosti).
Ataluren plasma concentrations in patients from 2 to less than 5 years old were consistent with those seen in patients above the age of 5 years receiving the 10/10/20 mg/kg dose regimen. 
Koncentracije atalurena v plazmi bolnikov, starih od 2 do manj kot 5 let, so bile skladne z vrednostmi, ki so jih videli pri bolnikih, starih več kot 5 let, ki so prejemali režim odmerjanja 10/10/20 mg/kg.
adefovir treatment of chronic hepatitis B and/or HIV 
Običajno se predpiše za aciklovir zdravljenje noric adefovir zdravljenje kroničnega hepatitisa B in/ali virusa HIV
But, take the next doses on time. 
Naslednje odmerke vzemite ob pravem času.